J&J-related uncertainties are behind us now
11/03/25 -"Yesterday, J&J announced it would not exercise its option to license HexaBody-CD38 (previously deemed to be Darzalex’s successor) from Genmab, thereby ending the uncertainty around this ..."
Pages
48
Language
English
Published on
11/03/25
You may also be interested by these reports :
08/12/25
Despite US tariff threats, drug pricing pressures and the persistent insistence from the US government to reshore manufacturing, the AV Big Pharmas ...
05/12/25
Against the backdrop of strong execution, with two outlook upgrades in 2025, backed by vigorous growth across all its focus areas (oncology, ...
28/11/25
Novo’s investors losing more weight than its patients
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...